Vitamin D-mediated hypercalcemia in multicentric Castleman's disease

J Bone Miner Metab. 2017 Jan;35(1):122-125. doi: 10.1007/s00774-015-0726-7. Epub 2015 Nov 23.

Abstract

Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder, which represents various symptoms caused by the hyperproduction of interleukin-6 (IL-6). However, case studies of MCD accompanied by hypercalcemia have rarely been reported thus far. A 78-year-old male had generalized fatigue, and his laboratory data revealed elevated serum calcium (Ca) and 1,25-dihydroxyvitamin D [1,25(OH)2D] levels (11.5 mg/dl and 80 pg/ml, respectively), while the serum intact parathyroid hormone level was low (4 pg/ml). Computed tomography showed multicentric lymphadenopathy. The serum IL-6 level was elevated (20.7 pg/ml), and pathological examination of a supraclavicular lymph node specimen led us to diagnose MCD. Moreover, immunostaining analysis showed that vitamin D-activating enzyme 25-hydroxyvitamin D 1-alpha-hydroxylase was expressed in lymph node macrophages. Prednisolone treatment improved the hypercalcemia and decreased the levels of 1,25(OH)2D and IL-6. We first reported a case of vitamin D-mediated hypercalcemia in MCD.

Keywords: 25-Hydroxyvitamin D 1-alpha-hydroxylase; Castleman disease; Hypercalcemia; Prednisolone; Vitamin D.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Castleman Disease / blood
  • Castleman Disease / drug therapy*
  • Humans
  • Hypercalcemia / blood
  • Hypercalcemia / chemically induced*
  • Hypercalcemia / drug therapy
  • Male
  • Parathyroid Hormone / blood
  • Prednisolone / administration & dosage
  • Vitamin D / administration & dosage*
  • Vitamin D / adverse effects*
  • Vitamin D / analogs & derivatives
  • Vitamin D / blood

Substances

  • Parathyroid Hormone
  • Vitamin D
  • 1,25-dihydroxyvitamin D
  • Prednisolone

Supplementary concepts

  • Multi-centric Castleman's Disease